

# Mark C Genovese

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/140798/publications.pdf>

Version: 2024-02-01

167  
papers

19,019  
citations

22099

59  
h-index

11581

135  
g-index

169  
all docs

169  
docs citations

169  
times ranked

13019  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years. <i>Modern Rheumatology</i> , 2023, 33, 64-72.	0.9	2
2	Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 469-479.	0.5	30
3	Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 184-192.	0.5	40
4	The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States. <i>ACR Open Rheumatology</i> , 2022, 4, 473-482.	0.9	4
5	Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study. <i>Journal of Rheumatology</i> , 2021, 48, 969-976.	1.0	12
6	Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs. <i>Journal of Rheumatology</i> , 2021, 48, 1230-1238.	1.0	29
7	Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study. <i>Lancet Rheumatology</i> , The, 2021, 3, e262-e269.	2.2	28
8	P171 Efficacy and safety of upadacitinib in patients with active PsA and inadequate response to biologic DMARDs (SELECT-PsA-2): a double-blind, randomised controlled Phase III trial. <i>Rheumatology</i> , 2021, 60, .	0.9	0
9	Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors. <i>Rheumatology</i> , 2021, 60, 4991-5001.	0.9	11
10	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 924-939.	1.5	466
11	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1108-1123.	2.9	339
12	Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies. , 2021, 8, 120-129.		5
13	Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity. <i>PLoS ONE</i> , 2021, 16, e0244187.	1.1	16
14	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 848-858.	0.5	123
15	Methotrexate in the Treatment of Idiopathic Granulomatous Mastitis. <i>Journal of Rheumatology</i> , 2020, 47, 924-927.	1.0	34
16	Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years follow-up. <i>Rheumatology</i> , 2020, 59, 292-302.	0.9	43
17	Unique Sjögren's syndrome patient subsets defined by molecular features. <i>Rheumatology</i> , 2020, 59, 860-868.	0.9	41
18	TNF-alpha inhibition for the treatment of cardiac sarcoidosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 546-552.	1.6	27

#	ARTICLE	IF	CITATIONS
19	P225â€fInhibition of structural joint damage with upadacitinib as monotherapy or in combination with MTX in patients with RA: one-year outcomes from the select Phase 3 programme. <i>Rheumatology</i> , 2020, 59, .	0.9	0
20	P235â€fGlucocorticoid dose is progressively reduced in Patients with rheumatoid arthritis (RA) receiving sarilumab: results from the open label EXTEND study. <i>Rheumatology</i> , 2020, 59, .	0.9	1
21	Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study. <i>Lancet Rheumatology</i> , The, 2020, 2, e527-e538.	2.2	59
22	O09â€fPooled safety analyses from Phase 3 studies of filgotinib in patients with RA. <i>Rheumatology</i> , 2020, 59, .	0.9	0
23	Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1290-1297.	0.5	61
24	Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 188.	1.6	2
25	Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1514-1525.	0.9	8
26	Interleukin-6 receptor blockade or TNF± inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. <i>Arthritis Research and Therapy</i> , 2020, 22, 206.	1.6	20
27	Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. <i>Lancet Rheumatology</i> , The, 2020, 2, e347-e357.	2.2	51
28	Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies. <i>RMD Open</i> , 2020, 6, e000987.	1.8	17
29	Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001095.	1.8	48
30	Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. <i>Arthritis Research and Therapy</i> , 2020, 22, 139.	1.6	21
31	Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001096.	1.8	3
32	Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 60.	1.6	14
33	The road to rheumatoid arthritis prevention: challenges and opportunities. <i>Clinical Rheumatology</i> , 2020, 39, 1379-1381.	1.0	6
34	Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 14.	1.6	27
35	Association of High Serum Interleukinâ€6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1456-1466.	2.9	30
36	Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Doubleâ€Blind, Phase <sc>II</sc> Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 1435-1446.	2.9	83

#	ARTICLE	IF	CITATIONS
37	Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. <i>Rheumatology</i> , 2020, 59, 3834-3844.	0.9	45
38	Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy. <i>RMD Open</i> , 2020, 6, e001490.	1.8	17
39	Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study. <i>Rheumatology and Therapy</i> , 2019, 6, 503-520.	1.1	12
40	Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2019, 71, 1788-1800.	2.9	284
41	Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 315.	3.8	210
42	Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1454-1462.	0.5	115
43	086 Safety and efficacy of filgotinib in a phase 3 trial of patients with active rheumatoid arthritis and inadequate response or intolerance to biologic disease modifying anti-rheumatic drugs. <i>Rheumatology</i> , 2019, 58, .	0.9	0
44	MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 887-895.	1.0	7
45	Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis. <i>BMC Rheumatology</i> , 2019, 3, 3.	0.6	18
46	Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. <i>RMD Open</i> , 2019, 5, e001017.	1.8	9
47	FR10075...SYSTEMATIC ANALYSIS OF INJECTION-SITE PAIN CAUSED BY SUBCUTANEOUS ADMINISTRATION OF THE ADALIMUMAB BIOSIMILAR FKB327 VERSUS ADMINISTRATION OF THE ADALIMUMAB REFERENCE PRODUCT VIA DIFFERENT DELIVERY METHODS. , 2019, , .		1
48	THU0173...FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR) BY RACE & GEOGRAPHIC REGION. , 2019, , .		0
49	THU0078...SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. , 2019, , .		5
50	SAT0132...LONG-TERM SAFETY, IMMUNOGENICITY AND EFFICACY IN RANDOMIZED, DOUBLE-BLIND, AND OPEN-LABEL EXTENSION STUDIES COMPARING FKB327, AN ADALIMUMAB BIOSIMILAR, WITH THE ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS. , 2019, , .		0
51	FR10092...SAFETY AND EFFICACY OF FILGOTINIB IN ACTIVE RHEUMATOID ARTHRITIS BY PRIOR BIOLOGICAL DMARD EXPOSURE IN PATIENTS WITH PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR). , 2019, , .		0
52	FR10154...SAFETY AND EFFICACY OF FILGOTINIB IN PATIENTS AGED 65 YEARS AND OLDER: RESULTS FROM A PHASE 3 STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR). , 2019, , .		2
53	AB0448...SAFETY AND EFFICACY OF FILGOTINIB IN JAPANESE PATIENTS ENROLLED IN A GLOBAL PHASE 3 TRIAL OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DMARDS. , 2019, , .		0
54	OP0029...SWITCHING BETWEEN THE JAK1-SELECTIVE INHIBITOR-UPADACITINIB AND ADALIMUMAB FOLLOWING INITIAL NON-RESPONSE: CLINICAL AND FUNCTIONAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS. , 2019, , .		1

#	ARTICLE	IF	CITATIONS
55	SAT0121â€¦EFFECT OF SARILUMAB ON GLYCOSYLATED HEMOGLOBIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DIABETES. , 2019, , .		2
56	LB0009â€¦ FIRST-IN-HUMAN STUDY OF NOVEL IMPLANTED VAGUS NERVE STIMULATION DEVICE TO TREAT RHEUMATOID ARTHRITIS. , 2019, , .		2
57	Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. RMD Open, 2019, 5, e000887.	1.8	27
58	FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension. Arthritis Research and Therapy, 2019, 21, 281.	1.6	34
59	Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. Journal of Rheumatology, 2019, 46, 7-18.	1.0	207
60	Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Annals of the Rheumatic Diseases, 2019, 78, 171-178.	0.5	66
61	Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial. Journal of Rheumatology, 2018, 45, 1085-1092.	1.0	28
62	Clinical Efficacy and Safety of Baminercept, a Lymphotoxin Î² Receptor Fusion Protein, in Primary Sjögren's Syndrome. Arthritis and Rheumatology, 2018, 70, 1470-1480.	2.9	56
63	Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. Rheumatology, 2018, 57, 900-908.	0.9	47
64	Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics. RMD Open, 2018, 4, e000581.	1.8	11
65	Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2018, 45, 14-21.	1.0	57
66	214â€¦Efficacy and safety of switching from adalimumab to sarilumab in an open-label extension of a phase III monotherapy trial in patients with active rheumatoid arthritis. Rheumatology, 2018, 57, .	0.9	0
67	233â€¦Durability, maintenance and effects of dose reduction following prolonged treatment with baricitinib. Rheumatology, 2018, 57, .	0.9	0
68	219â€¦Safety summary results of baricitinib focusing on serious infections events and preselected comorbidities. Rheumatology, 2018, 57, .	0.9	1
69	Phase II Study of ABTâ€¦122, a Tumor Necrosis Factor and Interleukinâ€¦17A Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate. Arthritis and Rheumatology, 2018, 70, 1778-1789.	2.9	77
70	ABTâ€¦122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukinâ€¦17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate. Arthritis and Rheumatology, 2018, 70, 1710-1720.	2.9	55
71	217â€¦Improvements in remission and low disease activity are achieved with ongoing sarilumab treatment, in patients with rheumatoid arthritis in two phase III studies. Rheumatology, 2018, 57, .	0.9	0
72	Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. Rheumatology, 2018, 57, 2001-2011.	0.9	34

#	ARTICLE	IF	CITATIONS
73	Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. <i>Rheumatology</i> , 2018, 57, 1972-1981.	0.9	30
74	Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. <i>Arthritis Research and Therapy</i> , 2018, 20, 57.	1.6	42
75	Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. <i>Rheumatology</i> , 2018, 57, 1423-1431.	0.9	31
76	Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. <i>Lancet, The</i> , 2018, 391, 2513-2524.	6.3	316
77	Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. <i>Rheumatology</i> , 2017, 56, kew370.	0.9	42
78	Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 932-942.	2.9	78
79	Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 694-700.	0.5	83
80	Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1078-1085.	0.5	76
81	Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 414-417.	0.5	94
82	Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1679-1687.	0.5	138
83	Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1751-1761.	2.9	65
84	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. <i>Lancet, The</i> , 2017, 389, 2317-2327.	6.3	316
85	Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 943-952.	2.9	42
86	Secukinumab in Active Rheumatoid Arthritis after Anti-TNF $\pm$ Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study. <i>Rheumatology and Therapy</i> , 2017, 4, 475-488.	1.1	25
87	O03. CLINICAL AND RADIOGRAPHIC OUTCOMES AFTER 3 YEARS OF SARILUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS. <i>Rheumatology</i> , 2017, 56, .	0.9	0
88	Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 145.	1.6	12
89	Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1979-1983.	0.5	45
90	Baricitinib in Patients with Refractory Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2016, 374, 1243-1252.	13.9	499

#	ARTICLE	IF	CITATIONS
91	Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures. <i>Arthritis Care and Research</i> , 2016, 68, 1579-1590.	1.5	43
92	Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. <i>Arthritis Research and Therapy</i> , 2016, 18, 198.	1.6	56
93	VX509 (Decernotinib), an Oral Selective JAK3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 46-55.	2.9	110
94	Efficacy and Safety of ABT494, a Selective JAK1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. <i>Arthritis and Rheumatology</i> , 2016, 68, 2857-2866.	2.9	172
95	Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naïve and TNF-IR Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 289-297.	1.0	28
96	Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial. <i>Journal of Rheumatology</i> , 2016, 43, 298-306.	1.0	37
97	Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 343-349.	1.0	17
98	Increased pretreatment serum IFN- $\gamma$ ratio predicts non-response to tumour necrosis factor $\alpha$ inhibition in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1757-1762.	0.5	59
99	Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 49-55.	0.9	40
100	Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 430-42.	0.4	23
101	Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 80.	1.6	20
102	Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 159.	1.6	104
103	Dr. Genovese comments. <i>Journal of Rheumatology</i> , 2015, 42, 1994-1994.	1.0	0
104	Efficacy and Safety of Tabalumab, an Anti-B-Cell Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 231-238.	0.5	8
105	Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1424-1437.	2.9	213
106	Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy. <i>Arthritis Research and Therapy</i> , 2015, 17, 127.	1.6	53
107	Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 333-340.	0.5	232
108	Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy. <i>Journal of Rheumatology</i> , 2015, 42, 1752-1760.	1.0	60

#	ARTICLE	IF	CITATIONS
109	OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2123-2129.	0.5	39
110	Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1703-1710.	2.9	25
111	Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1607-1615.	0.5	125
112	A1.72...Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A31.2-A31.	0.5	8
113	Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis: Longterm Data from the ACQUIRE Trial. <i>Journal of Rheumatology</i> , 2014, 41, 629-639.	1.0	33
114	Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. <i>Arthritis and Rheumatology</i> , 2014, 66, 3255-3264.	2.9	96
115	One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study. <i>Journal of Rheumatology</i> , 2014, 41, 414-421.	1.0	88
116	A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors. <i>Arthritis and Rheumatology</i> , 2014, 66, 1693-1704.	2.9	188
117	A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor Antagonist. <i>Journal of Rheumatology</i> , 2014, 41, 2120-2128.	1.0	57
118	Serum 14-3-3 is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2104-2113.	1.0	72
119	Sarilumab, a fully human monoclonal antibody against IL-6 in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1626-1634.	0.5	173
120	Long-Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment. <i>Arthritis and Rheumatology</i> , 2014, 66, 1987-1997.	2.9	48
121	Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2014, 370, 2295-2306.	13.9	350
122	Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2013, 159, 253.	2.0	381
123	Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure. <i>Journal of Rheumatology</i> , 2013, 40, 768-780.	1.0	108
124	Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study. <i>Arthritis Care and Research</i> , 2013, 65, 718-728.	1.5	65
125	A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1453-1460.	0.5	47
126	Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1461-1468.	0.5	66

#	ARTICLE	IF	CITATIONS
127	Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 863-869.	0.5	263
128	Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: Twenty-four-week results of an open-label, clinical practice study. <i>Arthritis Care and Research</i> , 2013, 65, 362-371.	1.5	56
129	Effect of Golimumab on Patient-reported Outcomes in Rheumatoid Arthritis: Results from the GO-FORWARD Study. <i>Journal of Rheumatology</i> , 2012, 39, 1185-1191.	1.0	38
130	Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy. <i>Journal of Rheumatology</i> , 2012, 39, 1546-1554.	1.0	61
131	Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. <i>Arthritis and Rheumatism</i> , 2012, 64, 617-629.	6.7	339
132	IL-17 receptor and its functional significance in psoriatic arthritis. <i>Molecular and Cellular Biochemistry</i> , 2012, 359, 419-429.	1.4	171
133	Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2011, 63, 373-382.	1.5	58
134	A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 846-854.	1.0	108
135	An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. <i>Arthritis and Rheumatism</i> , 2011, 63, 337-345.	6.7	190
136	Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. <i>Arthritis and Rheumatism</i> , 2011, 63, 939-948.	6.7	264
137	Edward D. Harris, Jr., MD, 1937-2010. <i>Arthritis and Rheumatism</i> , 2010, 62, 2623-2624.	6.7	0
138	Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1158-1161.	0.5	115
139	Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1129-1135.	0.5	135
140	An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2010, 363, 1303-1312.	13.9	369
141	First Report of Idiopathic Granulomatous Mastitis Treated with Methotrexate Monotherapy. <i>Journal of Rheumatology</i> , 2009, 36, 1559-1559.	1.0	38
142	Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 1429-1441.	1.0	89
143	Inhibition of p38: Has the fat lady sung?. <i>Arthritis and Rheumatism</i> , 2009, 60, 317-320.	6.7	182
144	Treatment of Rheumatoid Arthritis. , 2009, , 1119-1143.		7

#	ARTICLE	IF	CITATIONS
145	Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. <i>Arthritis and Rheumatism</i> , 2008, 58, 2652-2661.	6.7	193
146	Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. <i>Arthritis and Rheumatism</i> , 2008, 58, 2968-2980.	6.7	752
147	Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. <i>Journal of Rheumatology</i> , 2007, 34, 1040-50.	1.0	135
148	Long-Term Experience with Etanercept in the Treatment of Rheumatoid Arthritis in Elderly and Younger Patients. <i>Drugs and Aging</i> , 2006, 23, 167-178.	1.3	36
149	Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. <i>Arthritis and Rheumatism</i> , 2006, 54, 2793-2806.	6.7	1,462
150	Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. <i>Journal of Clinical Investigation</i> , 2006, 116, 2633-2642.	3.9	194
151	Biologic Therapies in Clinical Development for the Treatment of Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2005, 11, S45-S54.	0.5	30
152	Antigen microarray profiling of autoantibodies in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 2645-2655.	6.7	256
153	Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2005, 7, 407-415.	2.1	6
154	Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor Inhibition. <i>New England Journal of Medicine</i> , 2005, 353, 1114-1123.	13.9	1,157
155	Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 1232-42.	1.0	89
156	A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis. <i>Journal of Rheumatology</i> , 2005, 32, 2345-50.	1.0	3
157	Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. <i>Arthritis and Rheumatism</i> , 2004, 50, 1412-1419.	6.7	478
158	Treatment of rheumatoid arthritis with etanercept. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 311-328.	0.8	25
159	A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. <i>Arthritis Research</i> , 2004, 6, R73.	2.0	22
160	Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1014-1018.	6.7	10
161	Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. <i>Arthritis and Rheumatism</i> , 2002, 46, 1443-1450.	6.7	664
162	Treatment of rheumatoid arthritis with total lymphoid irradiation: Long-term survival. <i>Arthritis and Rheumatism</i> , 2001, 44, 1525-1528.	6.7	4

#	ARTICLE	IF	CITATIONS
163	Demyelinating and neurologic events reported in association with tumor necrosis factor ? antagonist: By what mechanisms could tumor necrosis factor ? antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?. Arthritis and Rheumatism, 2001, 44, 1977-1983.	6.7	296
164	Lymphocyte Cc Chemokine Receptor 9 and Epithelial Thymus-Expressed Chemokine (Teck) Expression Distinguish the Small Intestinal Immune Compartment. Journal of Experimental Medicine, 2000, 192, 761-768.	4.2	607
165	A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis. New England Journal of Medicine, 2000, 343, 1586-1593.	13.9	1,776
166	Joint and soft-tissue injection. Postgraduate Medicine, 1998, 103, 125-134.	0.9	31
167	077â€fImmunogenicity of Subcutaneous and Intravenous Tocilizumab as Monotherapy or in Combination with Disease-Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis. Rheumatology, 0, , .	0.9	0